These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
791 related articles for article (PubMed ID: 21097933)
1. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Chien EY; Liu W; Zhao Q; Katritch V; Han GW; Hanson MA; Shi L; Newman AH; Javitch JA; Cherezov V; Stevens RC Science; 2010 Nov; 330(6007):1091-5. PubMed ID: 21097933 [TBL] [Abstract][Full Text] [Related]
2. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism. Lane JR; Abramyan AM; Adhikari P; Keen AC; Lee KH; Sanchez J; Verma RK; Lim HD; Yano H; Javitch JA; Shi L Elife; 2020 Jan; 9():. PubMed ID: 31985399 [TBL] [Abstract][Full Text] [Related]
3. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855 [TBL] [Abstract][Full Text] [Related]
4. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895 [TBL] [Abstract][Full Text] [Related]
5. Progress in the structural prediction of G protein-coupled receptors: D3 receptor in complex with eticlopride. Obiol-Pardo C; López L; Pastor M; Selent J Proteins; 2011 Jun; 79(6):1695-703. PubMed ID: 21491496 [TBL] [Abstract][Full Text] [Related]
6. Selectivity and activation of dopamine D3R from molecular dynamics. Feng Z; Hou T; Li Y J Mol Model; 2012 Dec; 18(12):5051-63. PubMed ID: 22752545 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833 [TBL] [Abstract][Full Text] [Related]
8. Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs. Ferruz N; Doerr S; Vanase-Frawley MA; Zou Y; Chen X; Marr ES; Nelson RT; Kormos BL; Wager TT; Hou X; Villalobos A; Sciabola S; De Fabritiis G Sci Rep; 2018 Jan; 8(1):897. PubMed ID: 29343833 [TBL] [Abstract][Full Text] [Related]
9. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. Michino M; Free RB; Doyle TB; Sibley DR; Shi L Chem Commun (Camb); 2015 May; 51(41):8618-21. PubMed ID: 25896577 [TBL] [Abstract][Full Text] [Related]
10. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands. Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029 [TBL] [Abstract][Full Text] [Related]
13. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. Banala AK; Levy BA; Khatri SS; Furman CA; Roof RA; Mishra Y; Griffin SA; Sibley DR; Luedtke RR; Newman AH J Med Chem; 2011 May; 54(10):3581-94. PubMed ID: 21495689 [TBL] [Abstract][Full Text] [Related]
14. Structure-based drug design for dopamine D3 receptor. Feng Z; Hou T; Li Y Comb Chem High Throughput Screen; 2012 Dec; 15(10):775-91. PubMed ID: 22931309 [TBL] [Abstract][Full Text] [Related]
15. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214 [TBL] [Abstract][Full Text] [Related]
16. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies. Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464 [TBL] [Abstract][Full Text] [Related]
17. Antipsychotic haloperidol binding to the human dopamine D3 receptor: beyond docking through QM/MM refinement toward the design of improved schizophrenia medicines. Zanatta G; Nunes G; Bezerra EM; da Costa RF; Martins A; Caetano EW; Freire VN; Gottfried C ACS Chem Neurosci; 2014 Oct; 5(10):1041-54. PubMed ID: 25181639 [TBL] [Abstract][Full Text] [Related]
18. Determination of key receptor-ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology model. Sukalovic V; Soskic V; Sencanski M; Andric D; Kostic-Rajacic S J Mol Model; 2013 Apr; 19(4):1751-62. PubMed ID: 23300056 [TBL] [Abstract][Full Text] [Related]
19. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes. Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands. Li A; Mishra Y; Malik M; Wang Q; Li S; Taylor M; Reichert DE; Luedtke RR; Mach RH Bioorg Med Chem; 2013 Jun; 21(11):2988-98. PubMed ID: 23618707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]